Discover
ATOS
Atossa Therapeutics, Inc.
2.04
2 x 1.46
2 x 2.49
bid
ask
+
0.11
5.70%
2 @ 04:32 AM
2.00 -0.04 (1.96%)
| Ytd | -76.95% | |
| 1y | -83.41% |
1.92
day range
2.06
1.70
52 week range
19.35
| Open | 1.95 | Prev Close | 1.93 | Low | 1.92 | High | 2.06 | Mkt Cap | 20.35M |
| Vol | 142.98K | Avg Vol | 138.26K | EPS | -4.37 | P/E | N/A | Forward P/E | -3.81 |
| Beta | 1.23 | Short Ratio | 14.73 | Inst. Own | 28.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 4.30 | 200-d Avg | 8.16 | 1yr Est | 6.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.06 | -0.05 | 0.01 | 16.67% |
| 2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
| 2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
| 2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
| 2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-09 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
| 2023-11-14 | WEAVER GREGORY L | Officer and Director | 55.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 9.67M | 9.96M | 7.68% |
| 2024-09-29 | Vanguard Group Inc | 6.60M | 6.80M | 5.25% |
| 2024-09-29 | Geode Capital Management, LLC | 2.81M | 2.90M | 2.24% |
| 2024-09-29 | State Street Corporation | 1.73M | 1.78M | 1.38% |
| 2024-09-29 | Renaissance Technologies, LLC | 1.31M | 1.35M | 1.04% |
| 2024-09-29 | Northern Trust Corporation | 954.20K | 982.82K | 0.76% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 3.94M | 4.06M | 3.13% |
| 2024-10-30 | iShares Russell 2000 ETF | 3.27M | 3.37M | 2.60% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.67M | 1.72M | 1.33% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 1.30M | 1.34M | 1.04% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 1.07M | 1.10M | 0.85% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 676.43K | 696.73K | 0.54% |
Split
| Split | Date |
|---|---|
| 1 : 15 | 2026-02-02 |
| 1 : 12 | 2018-04-20 |
| 1 : 15 | 2016-08-26 |